“An Oral, Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib (BMS-986165), Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis” (2020) SKIN The Journal of Cutaneous Medicine, 4(6), p. s73. doi: 10.25251/skin.4.supp.73.